Navigation Links
Nektar Therapeutics Reports Third Quarter 2009 Financial Results
Date:11/4/2009

ge of development prior to regulatory approval for numerous reasons including, without limitation, safety and efficacy findings even after initial preclinical and clinical results have been positive; (ii) the timing or success of the commencement or end of clinical trials and commercial launch of partnered products may be delayed or unsuccessful due to slower than anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical trial design, clinical outcomes, or delay or failure in obtaining regulatory approval in one or more important markets; (iii) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future; (iv) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; (v) if Nektar is unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer; and (vi) certain other important risks and uncertainties set forth in Nektar's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2009, the Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 filed on August 5, 2009, the Current Report on Form 8-K filed today, and the most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 to be filed on or about November 5, 2009. Actual results could differ materially from the forward-looking statements contained in this press release. Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

                        NEKTAR THERAPEUTICS
          CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
           (In thousands, except 
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
3. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
4. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
5. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. Nektar Therapeutics Reports First Quarter 2009 Financial Results
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
11. Nektar Announces Retirement of Irwin Lerner from Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015   Tocagen Inc. , a ... from Tocagen,s ongoing investigational studies were presented at ... American Association of Neurological Surgeons (AANS)/Congress of Neurological ... 2015, in Washington, D.C. ... meeting with FDA and continues to advance towards ...
(Date:5/1/2015)... 01, 2015 OncoTAb, Inc., ... spin-out company, announced that Pinku Mukherjee, Ph.D. has received ... Board of Governors’ highest faculty honor. Mukherjee received the ... , for her innovative research and development of cancer ... represents a crowning moment in my scientific career,” said ...
(Date:5/1/2015)... LONDON , May 1, 2015 ... following equities: Genetic Technologies Ltd (NASDAQ: GENE ... Thermo Fisher Scientific Inc. (NYSE: TMO ), ... Inc. (NYSE: PKI ). Free research report ... http://get.Investor-Edge.com/pdf/?c=Genetic%20Technologies&d=01-May-2015&s=GENE . On Thursday, April 30, 2015, the ...
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2
... Benefiting from recent investments in production and enormous demand ... record quarter. The leading developer of topical biotechnology for hair ... over Q1 of 2010. It was the fastest growth since ... "Although Q1 delivered a stellar number — made ...
... Inc. ("Radius") today announced that the company has raised ... $66 million in equity financing and a commitment by ... to a $25 million multi-draw term loan facility. Five ... Capital, Nordic Bioscience ("Nordic"), and Ipsen Pharma SAS ("Ipsen") ...
... protein isolated from beneficial bacteria found in yogurt and ... for inflammatory bowel disorders (IBD), suggests a study led ... Ph.D. The study, published May 23 in the ... protein, called p40, was effective as an intervention in ...
Cached Biology Technology:First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin 2First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin 3Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 2Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 3Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 4Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 5Protein from probiotic bacteria may alleviate inflammatory bowel disorders 2Protein from probiotic bacteria may alleviate inflammatory bowel disorders 3
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
(Date:3/23/2015)... March 23, 2015 SoundView Technology Group issues a ... NXTD ) Wocket smart wallet. SoundView was one of the ... their experience with the Wocket in multiple scenarios and outlets. ... Foods and other retailers, making both debit and credit card ... also says, "If the company meets their plans in 2015, ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... mobile sequences of DNA left over from viruses, called transposons ... the genome, pose a significant threat to the genetic integrity ... elements are believed to comprise as much as 50 percent ... do to an organism,s DNA, an immune-like response has evolved ...
... generate millions of supercharged stem cells, which can then turn ... itself, has been patented at the University of Central Florida. ... holy grail of sorts in the medical world, because they ... of the most challenging diseases in our time, such as ...
... a simple, paper-based test for drug-resistant tuberculosis (TB) is ... chemist, whose project just received a $1.6 million point-of-care ... initiative created by the Bill & Melinda Gates Foundation. ... minds across scientific disciplines to work on solutions that ...
Cached Biology News:Defending the genome 2Defending the genome 3UCF patented on induced pluripotent stem cells, iPS cells 2University of Texas chemist receives major grant to improve detection of drug-resistant tuberculosis 2
...
... HyPer is the first fully genetically encoded ... of intracellular hydrogen peroxide (H2O2), one of ... on the basis of yellow fluorescent protein ... coli protein OxyR (OxyR-RD), HyPer demonstrates submicromolar ...
Alexa Fluor 647 anti-mouse Qa-2...
... cDNA normalization is essential for hunting ... high-throughput approaches, such as EST sequencing ... Evrogen TRIMMER-DIRECT kit is developed for ... sequences and intended for directional cloning. ...
Biology Products: